China’s First Filing! Bao Pharma’s IgG-Degrading Enzyme KJ103 NDA Accepted by China’s NMPA and Granted Priority Review

Shanghai, China, 4 June 2026 — Shanghai Bao Pharmaceutical Co., Ltd. (“Bao Pharma”) today announced that the New Drug Application (NDA) for its independently developed KJ103 for Injection (“KJ103”) has been accepted by the National Medical Products Administration (NMPA) of China and has been granted Priority Review status. KJ103 is being developed for desensitisation treatment in highly sensitised kidney transplant candidates.

For more information, please visit the following link: https://www.baopharma.com.cn/zuixinxiaoxi/54

About Shanghai Bao Pharmaceutical

Founded in 2019, Shanghai Bao Pharmaceutical Co., Ltd. is an innovative biotechnology company specializing in clinical development, synthetic biology and recombinant biologics. The company focuses on replacing traditional biochemically extracted products and upgrading validated therapies, building a diversified pipeline across high-volume subcutaneous drug delivery, autoimmune diseases and assisted reproduction. With leading chassis-cell engineering capabilities, a stable commercial manufacturing system, and an international R&D team, Bao Pharma aims to become a global frontrunner in recombinant biologics.

Forward-Looking Statement

This press release may contain forward-looking statements based on current expectations, assumptions, and projections made by the management of Shanghai Bao Pharmaceutical Co., Ltd. (“Bao Pharma”). These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such statements include, but are not limited to, descriptions of business strategies, future operational plans, R&D progress, clinical-trial outcomes, commercial prospects, and financial performance. Except as required by law or regulation, Bao Pharma undertakes no obligation to update or revise any forward-looking statement to reflect new information, future events, or other changes. This press release is for informational purposes only and does not constitute investment advice or an offer to purchase securities of the company.